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Statement of Translational Relevance
Durable tumor regression and even cures can be achieved in multiple myeloma patients by immunotherapeutic approaches, such as allogeneic stem cell transplantation and donor lymphocyte infusion. However, low rate of sustained remissions impedes the success of this therapeutic approach. Currently, much emphasis is placed on the role of the tumor microenvironment in tumor cell immune escape. We here describe a previously underappreciated mechanism of immune escape induced by the microenvironment: cell adhesion-mediated immune resistance (CAM-IR). To modulate this resistance, we provide a rational combination of molecularly targeted and immunological strategy, by combining cytotoxic T cells and two clinically tested therapeutics. These findings add a new perspective to microenvironment-induced immune escape, which lead to better understanding of mechanisms involved in immune evasion and can guide clinical testing of potential drug-
Introduction
Multiple myeloma (MM) has long been the paradigmatic model for investigating the role of the microenvironment in blood cancers (1) . The natural niche of MM, the bone marrow (BM), is a milieu of growth factors and cytokines that provides optimal conditions for MM cell proliferation and survival. Furthermore, the BM microenvironment contributes to resistance against various therapies. Interaction of MM cells with accessory cells of the bone marrow microenvironment induces pleiotropic anti-apoptotic mechanisms, thereby rendering MM cells resistant to established therapeutic regimens (e.g. glucocorticoids, DNA damaging chemotherapy) (2) as well as investigational anti-MM agents (3;4) . This concept, generally known as cell adhesion-mediated drug resistance (CAM-DR), is considered as one of the major obstacles hindering successful treatment(5-7). Next to these well documented roles on MM cell survival, growth and drug resistance, recent evidence indicates that the BM microenvironment facilitates MM cells to escape the immune system (8) . This is particularly important, because despite the therapeutic potential of cellular immunotherapies, such as allogeneic stem cell transplantation or donor lymphocyte infusions (9) (10) (11) , the majority of MM patients receiving these therapies do not achieve sustained remissions (12;13) . Several immunosuppressive factors such as IDO, TGF-β or VEGF, have been shown to hamper T cell activation or proliferation in the tumor microenvironment (14) 
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Material & Methods
Cell culture
The luciferase (Luc)-transduced human MM cell lines U266 and UM9 were maintained in RPMI1640 (Invitrogen), supplemented with 10% fetal bovine serum (FBS; Integro BV) and antibiotics (penicillin/streptomycin; Life Technologies) as previously described (18) . The authenticity was confirmed by partial HLA-typing carried out maximal six months prior to the most recent experiment. The bone marrow stromal cell line HS-5 and bone marrow stromal cells from MM patients (pBMSC) or from healthy individuals (hBMSC) were cultured in DMEM (Invitrogen) with 10% FBS and antibiotics. BMSC were used in experiments until passage six. All BM samples were obtained after informed consent and approved by the institutional medical ethical committee. Human umbilical vein derived endothelial cells (HUVEC) were obtained from Lonza and cultured in EGM-2 medium (Lonza).
The HLA-DP4 restricted, minor histocompatibility antigen (mHag)-specific CD4 + CTL clone 3AB11; the HLA-A2 restricted mHag specific CD8 + CTL clone HA-1; the HLA-A2 specific CD8 + CTL clone 1E4; and the HLA-A2 restricted WT-1 specific TCR transferred polyclonal CTLs were previously described in detail with respect to their antigen-specific and HLArestricted cytotoxic capacity against the relevant HLA-matched and antigen-positive MM cells (18) (19) (20) (21) . CTLs were expanded using a feeder cell-cytokine mixture and cryopreserved until use as described (19) .
Reagents
RGDw peptide (provided by Prof. P. de Groot; University Medical Center Utrecht, the Netherlands) (22) was used at a concentration of 200µM. Neutralizing antibody against Fas ligand (BD Pharmingen) was used at a concentration of 10µg/ml. Bortezomib and YM155
(both Selleck Chemicals) were dissolved in dimethyl sulfoxide at a concentration of 200µM and 1mM respectively and aliquoted for storage until use. Both were diluted in culture medium to the concentrations indicated in each experiment.
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Granzyme B Enzyme linked immunosorbent assay (ELISA)
The granzyme B (GzB) content of cell-free supernatants was determined using a commercial ELISA kit (Pelipair, Sanquin, Amsterdam, NL) according to the manufacturer's instructions.
Transwell experiments
Accessory cells were seeded in 24 well plates at a density of 6x10 4 
subcutaneously into RAG2
−/− γ C −/− mice, as described previously (25) . As controls, uncoated scaffolds were implanted in the same mice and MM cells were injected directly into the scaffold. Ten days after implantation, tumors growing in the scaffolds were treated with CD4 + CTL 3AB11 (5x10 6 CTLs per scaffold), by directly injecting the CTLs into the scaffold. An identical set of scaffolds was left untreated. At the day of T cell injection, subcutaneous pumps (Alzet 1007D, Charles River, Sulzfield, Germany) were implanted which were either filled with PBS or with 2.08µg/µl YM155 (Selleckchem) diluted in PBS delivering 1 mg/kg/ day YM155 continuously. Pumps were removed after 5 days. Bioluminescent imaging was performed as described previously (26).
Statistical and synergy analyses
The differences in triplicate measurements were determined by statistical tests as indicated in the figure legends. P values below 0.05 were considered as significant. 
Accessory cells inhibit CTL-mediated MM lysis in a cell-cell contact dependent fashion
To evaluate the mechanism of the protective effect of accessory cells we first carried out transwell experiments, in which MM cells and accessory cells were either co-cultured in direct contact, or separated by micropore membrane inserts. As expected, accessory cells significantly inhibited the MM cell lysis by CTLs in co-cultures when they were in direct
Research. contact with MM cells (Fig 1B) . However, when accessory cells were separated by a transwell from MM cells, the inhibitory capacity of HUVEC and pBMSC was almost completely lost and that of HS-5 diminished substantially (Fig 1B) . Finally, we carried out extended transwell assays, in which not only accessory cells but also MM cells were cultured in the bottom chamber of the transwells (Fig 1C) . Also under these conditions no inhibition of lysis occured, indicating that accessory cells protected MM cells from CTL mediated lysis mainly via cell-cell contacts. Therefore we next examined whether blocking the adhesion of Fig. S3 ) and substantially decreased their capacity to protect MM cells from CTL-mediated lysis ( Fig. 2A-B) . These findings emphasized the importance of cell cell-contacts for the capacity of accessory cells to protect MM cells from CTLs. However, the inhibitory effect could not be attributed to integrin dependent cell-adhesion alone, since mere binding of MM cells to fibronectin, vitronectin or laminin coated wells did not induce an inhibitory effect on CTL mediated lysis of MM cells (Fig. 2C-D) .
Accessory cells induce immune resistance as well as immune suppression
CTLs are known to initiate target cell death via granzyme-(30) or death receptor-mediated mechanisms(31), both of which require CTL activation. Hence, the accessory cell induced inhibition of CTL-mediated lysis in our assays could be either due to suppression of T cells and/or to an acquired resistance in MM cells against the lysis mechanisms of CTLs. To differentiate between these, we measured granzyme-B excretion and Fas ligand (FasL) expression on CTLs as a marker for T cell activation upon co-culture with MM cells and accessory cells. The CD4 + CTL-mediated lysis of UM9 cells was inhibited by the accessory cells (Fig. 3A) , without a reduction in granzyme-B release (Fig. 3B) 
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upregulation on the CTLs (Supplementary Fig. S4A ), excluding . These results excluded T cell suppression as a mechanism and revealed the development of cell adhesion-mediated immune resistance (CAM-IR) in UM9 cells. For CD8 + CTLs, accessory cells not only inhibited the lysis of U266 cells (Fig. 3C ), but also reduced granzyme-B production (Fig. 3D) , suggesting the induction of T cell suppression. However, the upregulation of FasL levels on the CD8 + CTLs did not diminish, thus renouncing absolute T cell suppression ( Supplementary Fig. S4B ). Development of immune resistance in U266 cells could not be excluded in these assays. Hence, we addressed this by further analyzing regulators of the apoptotic pathways in both UM9 and U266 upon interaction with accessory cells.
Fas downregulation as a mechanism of CAM-IR
To fig. S5 ). Furthermore, FasL blocking antibodies almost completely reverted the bortezomib induced augmentation of CD8 + CTL-mediated lysis (Fig. 4D) .
Altogether, these assays indicated Fas downregulation as a mechanism of immune 
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resistance. The action of bortezomib in this system was probably not restricted to Fas modulation only, since the anti FasL antibodies did not completely block bortezomib-induced effects on CD4 + CTL mediated lysis of MM cells (Fig. 4D ).
Downstream mechanisms of CAM-IR in MM cells
The experiments with bortezomib indicated Fas downregulation as a possible mechanism of immune resistance, but also implicated the existence of other mechanisms. Therefore, we next investigated whether adhesion of UM9 and U266 to accessory cells altered the expression of inhibitors of apoptosis proteins (IAPs) and of Bcl-2 family proteins, all involved in granzyme-and death receptor-mediated apoptotic pathways utilized by CTLs (33).
Consistent with previous reports (34), we observed a modest increase of survivin and Mcl-1 both in U266 and UM9 cells upon co-culture with HS-5 ( Fig. 5A) . To ascertain the role of these proteins in immune resistance, we used the small molecule YM155, which represses survivin and Mcl-1 levels(35) (Supplementary Fig.6A ). Indeed when we combined YM155
with CTLs in the presence or absence of accessory cells, the CTL-mediated lysis of U266
and UM9 was markedly increased (Fig. 5B ) in a synergistic fashion ( Supplementary Fig.   S6B ), while there was no influence of YM155 on T cell activation ( Supplementary Fig. S6C ).
To validate the involvement of survivin in CAM-IR, we suppressed the expression of survivin in UM-9 cells by lentiviral shRNA transduction (Fig. 5C ). Indeed, survivin shRNA treated UM9 cells had a substantially lower capacity to induce CAM-IR (Fig. 5D ), confirming the involvement of this anti apoptotic protein in CAM-IR.
In vivo efficacy of CTL and YM155 combination therapy
Since the in vitro experiments with YM155 were successful in abrogating CAM-IR, we set out to test this combination therapy in a novel in vivo humanized mouse model, in which a human bone marrow microenvironment can be generated by subcutaneous inoculation of ceramic scaffolds coated with human BMSCs (36) . Thus, we compared the CTL-mediated
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Consistent with the in vitro data, T cells completely inhibited the outgrowth of MM cells, which
were not in the humanized microenvironment. In contrast, the outgrowth of MM cells in the humanized scaffolds was not clearly inhibited by T cells (Fig. 6A) , confirming the existence of CAM-IR in vivo. We next investigated if this CAM-IR could be abrogated by combination of CTLs with YM155. Mice were thus treated with CTLs alone, YM155 alone, or both CTLs and YM155. Similar to the first experiment, CTLs were unable to eliminate MM cells that were implanted in human MSC coated scaffolds. YM155 therapy alone did also not show a beneficial effect on tumor growth. In striking contrast however,the YM155 and CTL combination achieved a substantial antitumor effect (Fig. 6B) , demonstrating that YM155 can abrogate CAM-IR also not only in vitro bu also in vivo. vitronectin (VN) (both 5µg/ml) and laminin (50µg/ml). MM-cell specific CTLs were added after 16 h. Experimental conditions were performed in triplicate. Survival of MM cells was determined by CS-BLI after 24 hours of co-culture with CTLs. Differences in T cell lysis were evaluated by using unpaired two tailed student's t test. *= p<0.05; **= p<0.01 ***= P<0.001. 
